Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C17H19N3.ClH |
| Molecular Weight | 301.814 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CN1CCN2[C@H](C1)C3=CC=CC=C3CC4=CC=CN=C24
InChI
InChIKey=SISMRXGXKXMBKT-PKLMIRHRSA-N
InChI=1S/C17H19N3.ClH/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20;/h2-8,16H,9-12H2,1H3;1H/t16-;/m1./s1
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C17H19N3 |
| Molecular Weight | 265.3529 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Esmirtazapine (S-(+)mirtazapine or ORG-50081) is an enantiomer of mirtazapine (REMERON®), a high-affinity antagonist at 5-HT2/5-HT3 and H1 receptors, used in the treatment of depression. Esmirtazapine has a shorter plasma half-life than the R(−) enantiomer. Esmirtazapine is preferentially metabolized into an 8-hydroxy glucuronide. Organon was developing esmirtazapine for the treatment of hot flushes (vasomotor symptoms) associated with the menopause and insomnia.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Treating age-related changes in somatotrophic hormones, sleep, and cognition. | 2001 Sep |
|
| Pathophysiology of depression and mechanisms of treatment. | 2002 Mar |
|
| Behavioral disturbances in dementia. | 2003 Mar |
|
| Repeated treatment with mirtazepine induces brain-derived neurotrophic factor gene expression in rats. | 2005 Dec |
|
| Onset of improvement and response to mirtazapine in depression: a multicenter naturalistic study of 4771 patients. | 2005 Mar |
|
| [Compliance in psychiatry: results of a survey of depressed patients using orally disintegrating tablet]. | 2006 |
|
| Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review. | 2006 Dec |
|
| Improvement in cognitive and psychosocial functioning and self image among adolescent inpatient suicide attempters. | 2006 Dec 29 |
|
| Prophylaxis of migraine. | 2006 Sep |
|
| Family history, early adversity and the hypothalamic-pituitary-adrenal (HPA) axis: Mediation of the vulnerability to mood disorders. | 2007 |
|
| [Differentiated approach to the therapy of endogenous anxious depression]. | 2007 |
|
| [Depressive disturbances during antiviral therapy in patients with type C hepatitis]. | 2007 |
|
| Post-traumatic stress disorder. | 2007 Aug 1 |
|
| A survey of combination antidepressant use in Australia. | 2007 Feb |
|
| In silico prediction of pregnane X receptor activators by machine learning approaches. | 2007 Jan |
|
| "Add-On"-therapy with an individualized preparation consisting of free amino acids for patients with a major depression. | 2007 Jun |
|
| Essential tremor. | 2007 May 1 |
|
| Treatment of depression as part of end-of-life care. | 2008 |
|
| Toward achieving optimal response: understanding and managing antidepressant side effects. | 2008 |
|
| 5-HT(2A) inverse-agonists for the treatment of insomnia. | 2008 |
|
| Triple reuptake inhibitors: the next generation of antidepressants. | 2008 Dec |
|
| Pharmacological management of panic disorder. | 2008 Feb |
|
| Outcomes after isolated mirtazapine (Remeron) supratherapeutic ingestions. | 2008 Jan |
|
| A postmenopausal woman presenting with Ekbom syndrome associated with recurrent depressive disorder: a case report. | 2008 Jul 22 |
|
| Neuropharmacology. | 2008 Oct |
|
| Triple reuptake inhibitors: a premise and promise. | 2008 Sep |
|
| Routing protocols in wireless sensor networks. | 2009 |
|
| A new paradigm for the prediction of antidepressant treatment response. | 2009 |
|
| Brain-derived neurotrophic factor: role in depression and suicide. | 2009 |
|
| Psychopharmacology of ADHD in pediatrics: current advances and issues. | 2009 |
|
| Mirtazapine: a review of its use in major depression and other psychiatric disorders. | 2009 |
|
| Incidence of major malformations in infants following antidepressant exposure in pregnancy: results of a large prospective cohort study. | 2009 Apr |
|
| Brain potentials of conflict and error-likelihood following errorful and errorless learning in obsessive-compulsive disorder. | 2009 Aug 12 |
|
| Early presentation following overdose of modified-release paracetamol (Panadol Osteo) with biphasic and prolonged paracetamol absorption. | 2009 Aug 7 |
|
| Ethyl carbamate in alcoholic beverages from Mexico (tequila, mezcal, bacanora, sotol) and Guatemala (cuxa): market survey and risk assessment. | 2009 Jan |
|
| Management of difficult urticaria. | 2009 Jul |
|
| Treatment with selective serotonin reuptake inhibitors and mirtapazine results in differential brain activation by visual erotic stimuli in patients with major depressive disorder. | 2009 Jun |
|
| Undertreatment of menopausal symptoms and novel options for comprehensive management. | 2009 Nov |
|
| Algorithms for the assessment and management of insomnia in primary care. | 2009 Nov 3 |
|
| Fibromyalgia and myofascial pain syndrome-a dilemma. | 2009 Oct |
|
| Sexual side-effects of contemporary antidepressants: review. | 2009 Sep |
|
| Extreme thermal sensitivity and pain-induced sensitization in a fibromyalgia patient. | 2010 |
|
| Comorbidities of migraine. | 2010 |
|
| Local smoke-free policy development in Santa Fe, Argentina. | 2010 Apr |
|
| 3D-QSAR design of new escitalopram derivatives for the treatment of major depressive disorders. | 2010 Apr-Jun |
|
| Cancer cachexia: traditional therapies and novel molecular mechanism-based approaches to treatment. | 2010 Dec |
|
| Gene expression profiling in whole blood identifies distinct biological pathways associated with obesity. | 2010 Dec 1 |
|
| Mania associated with mirtazepine treatment and mixed depression. | 2010 Jan |
|
| Behavioral and developmental changes in rats with prenatal exposure of mirtazapine. | 2010 Jul-Sep |
|
| QEEG Measures in Huntington's Disease: A Pilot Study. | 2010 Oct 25 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 22:12:07 GMT 2025
by
admin
on
Mon Mar 31 22:12:07 GMT 2025
|
| Record UNII |
J12BQ47O1N
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
71576069
Created by
admin on Mon Mar 31 22:12:07 GMT 2025 , Edited by admin on Mon Mar 31 22:12:07 GMT 2025
|
PRIMARY | |||
|
1448014-35-4
Created by
admin on Mon Mar 31 22:12:07 GMT 2025 , Edited by admin on Mon Mar 31 22:12:07 GMT 2025
|
PRIMARY | |||
|
J12BQ47O1N
Created by
admin on Mon Mar 31 22:12:07 GMT 2025 , Edited by admin on Mon Mar 31 22:12:07 GMT 2025
|
PRIMARY | |||
|
DBSALT002352
Created by
admin on Mon Mar 31 22:12:07 GMT 2025 , Edited by admin on Mon Mar 31 22:12:07 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
|
||
|
|
RACEMATE -> ENANTIOMER |
